Drug Trial Radar · NCT06821698
To Determine the Effect of KP-001 on Rosuvastatin, Caffeine PK and the Effect of Fluvoxamine on KP-001 PK in Volunteers
Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Feb 13, 2025
Primary completion
May 20, 2025
Study completion May 20, 2025
Sponsor
- Lead sponsor
- Kaken PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Feb 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Part 1 will evaluate the effects of KP-001 as an inhibitor of BCRP on the PK of rosuvastatin. In the Treatment Period 1, a single dose of rosuvastatin will be administered. In the Treatment Period 2, KP-001 will be administered once daily for 7 days and a single dose of rosuvastatin will be administered. Blood PK assessments of rosuvastatin will be performed until 48 hours postdose in each Treatment Period. Part 2 will evaluate the effects of KP-001 as an inducer and inhibitor of CYP1A2 on the PK of caffeine. A single dose of caffeine will be administered in the Treatment Period 1. KP-001 will be administered once daily for 10 days and a single dose of caffeine will be administered in the Treatment Period 2. Blood PK assessments of caffeine will be performed until 24 hours postdose in each Treatment Period. Part 3 will evaluate the effects of fluvoxamine as an inhibitor of CYP1A2 on the PK of KP-001. A single dose of KP-001 will be administered in the Treatment Period 1. Fluvoxamine will be administered as a single dose on the first day and then twice daily for 5 days and a single dose of KP-001 will be administered in the Treatment Period 2. Blood PK assessments of KP-001 will be performed until 48 hours postdose in each Treatment Period.
Conditions
- Healty Volunteers
Interventions
KP-001Drug
KP-001 100 mg dry syrup
Rosuvastatin calcium10mgDrug
A oral dose of 10 mg tablet
Caffeine citrateDrug
100 mg oral solution
FluvoxamineDrug
50 mg tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK parameters of rosuvastatin in plasma: AUCinfTime frame: 48hour
- PK parameters of rosuvastatin in plasma: CmaxTime frame: 48hour
- PK parameters of caffeine in plasma: AUCinfTime frame: 24hour
- PK parameters of caffeine in plasma: CmaxTime frame: 24hour
- PK parameters of KP-001 in plasma: AUCinfTime frame: 48hour
- PK parameters of KP-001 in plasma: CmaxTime frame: 48hour
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel International Early Phase Clinical Unit
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.